Cabaletta Bio Reports Q2 2026 Results, Cash Runway to Mid-2027, and Key Clinical Milestones
CABA has more than doubled off its 52-week low of $1.26.
Summary
Cabaletta Bio reported Q2 2026 financial results with a $51.0M net loss and $225.1M in cash, funding operations into mid-2027. The company also provided key clinical updates, including registrational data expected in mid-2027 and a new SSc-ILD cohort starting in 4Q26.
Key Events · Earnings and Guidance · CABA
-
Q2 2026 Financial Results
Net loss of $51.0 million, with R&D expenses of $44.4 million and G&A of $7.6 million. Cash position of $225.1 million as of June 30, 2026.
-
Cash Runway Extended to Mid-2027
Management expects the $225.1 million cash balance to fund operations into mid-2027, consistent with prior guidance.
-
Registrational Myositis Data on Track
RESET-Myositis registrational cohort data expected in mid-2027, with a BLA submission planned for 2H27 if successful.
-
New SSc-ILD Cohort to Initiate in 4Q26
A single-arm registrational study in approximately 25 patients with SSc-associated ILD is anticipated to begin in 4Q26.
Analysis · CABA · Life Sciences
Cabaletta Bio reported a net loss of $51.0 million for Q2 2026, with R&D expenses rising to $44.4 million as the company advances its rese-cel CAR T therapy. The company holds $225.1 million in cash, which it expects to fund operations into mid-2027. The filing also provides a detailed clinical update: registrational RESET-Myositis data is on track for mid-2027 with a BLA submission planned for 2H27, a new SSc-associated ILD cohort of approximately 25 patients is set to initiate in 4Q26, and the PC-free approach is being incorporated into RESET-MG. These milestones are material for a late-stage biotech with a going-concern warning, as they define the path to potential approval and the timeline for capital needs.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1615 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CABA was trading at $2.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $464.7M. The 52-week trading range was $1.26 to $4.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.